F Miglietta, A Fabi, D Generali, M V Dieci, G Arpino, G Bianchini, S Cinieri, P F Conte, G Curigliano, M De Laurentis, L Del Mastro, S De Placido, A Gennari, F Puglisi, A Zambelli, F Perrone, V Guarneri
Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability and survival prolongation we have witnessed in the last years for advanced disease. However, although chemotherapy still represents the mainstay of TN mBC management, in the past years, several novel effective agents have been developed and made available in the clinical practice setting. Within this framework, a panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers, addressed 26 high-priority statements, including grey areas, regarding the management of TN mBC...
March 2023: Cancer Treatment Reviews